| Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. | |
| | |
MedLine Citation:
|
PMID: 18684126 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Recombinant factor VIIa (rFVIIa, NovoSeven) has been licensed for treatment of haemophilia with inhibitors in Europe since 1996 and in North America since 1999. Overall, approximately 1.5 million doses have since been administered. Safety data from licensure to April 2003 revealed 25 thromboembolic (TE) adverse events (AE) from over 700 000 doses given, a remarkably low incidence of TE events. Recent reports have cited a higher prevalence of TE events with rFVIIa use, especially when used off-label. This report reviews the TE and fatal events with use of rFVIIa for congenital and acquired haemophilia A or B from May 2003 to December 2006. Approximately 800 000 standard doses of rFVIIa have been administered during this time frame. All clinical trials, spontaneous and solicited reports, as well as a detailed literature review, were included in the data analysis. There were a total of 30 TE events and 6 TE-associated fatal events. Spontaneous reports captured 14/71 (20%) TE/AE and 2/34 TE-associated/total fatal events. From solicited reports, 5/40 (12.5%) were associated with a TE and 1/32 TE-associated fatal events. Literature review revealed 11/19 (58%) TE events and 3/6 TE-associated fatal events. Despite the use of high-dose rFVIIa (270 mug kg(-1)) in some clinical trials and registries, rFVIIa appears safe, when used for congenital and acquired haemophilia. The prevalence of TE associated with rFVIIa use is less than 4/100 000 and a TE-associated fatal event is also extremely rare. However, use of rFVIIa for off-label indications should continue to be monitored closely via clinical trials and carefully designed registries. |
| | |
Authors:
|
T Abshire; G Kenet |
Related Documents
:
|
20209396 - Analyses of suicidal deaths with shotguns in istanbul, 1998-2007. 6356886 - The case of emmett-dunne. a personal reminiscence. 15113496 - Suicide and attempted suicide in france: results of a general practice sentinel network... 16139106 - Forensic case profiling aspects on multiple homicides from the cologne-bonn metropolita... 620866 - Yersinia enterocolitica as a cause of erythema nodosum. 15448506 - Primary meningococcal conjunctivitis in an adult. |
Publication Detail:
|
Type: Journal Article; Review Date: 2008-08-04 |
Journal Detail:
|
Title: Haemophilia : the official journal of the World Federation of Hemophilia Volume: 14 ISSN: 1365-2516 ISO Abbreviation: Haemophilia Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-10-21 Completed Date: 2008-12-10 Revised Date: 2009-10-21 |
Medline Journal Info:
|
Nlm Unique ID: 9442916 Medline TA: Haemophilia Country: England |
Other Details:
|
Languages: eng Pagination: 898-902 Citation Subset: IM |
Affiliation:
|
Aflac Cancer Center and Blood Disorders Service, Emory University, Atlanta, GA, USA. thomas.abshire@emory.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Child Factor IX / immunology Factor VIII / immunology Factor VIIa / adverse effects*, therapeutic use Hemophilia A / drug therapy*, immunology Hemophilia B / drug therapy*, immunology Humans Isoantibodies / blood Male Middle Aged Recombinant Proteins / adverse effects, therapeutic use Thromboembolism / chemically induced Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Isoantibodies; 0/Recombinant Proteins; 0/recombinant FVIIa; 9001-27-8/Factor VIII; 9001-28-9/Factor IX; EC 3.4.21.21/Factor VIIa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A survey of adherence to haemophilia therapy in six European countries: results and recommendations.
Next Document: Altered pharmacology in the intensive care unit patient.